NCT07459543 2026-03-09
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Phase 4 Not yet recruiting
Bristol-Myers Squibb
Dana-Farber Cancer Institute
University of Oklahoma
Charite University, Berlin, Germany
Hull University Teaching Hospitals NHS Trust
Zealand University Hospital
Clinigen, Inc.
University Hospitals Cleveland Medical Center
Goldman, Butterwick, Fitzpatrick and Groff
Clinigen, Inc.
University of Zurich
Wyeth is now a wholly owned subsidiary of Pfizer